The use of second generation antipsychotics in children and adolescents with bipolar disorder and schizophrenia: A summary of the AHRQ comparative effectiveness review

2013 ◽  
Vol 2 (11) ◽  
pp. 350-352
Author(s):  
Jeani Pulsipher ◽  
Gary M. Levin
Keyword(s):  
Bipolar Disorder ◽  
Adverse Effects ◽  
Children And Adolescents ◽  
Mood Disorders ◽  
Comparative Effectiveness ◽  
Second Generation ◽  
Pediatric Patients ◽  
Healthcare Research ◽  
Second Generation Antipsychotics

Second generation antipsychotics (SGAs) can be effective in treating mood disorders in pediatric patients; however, these medications also present with a risk of serious adverse effects. A recent review by the Agency for Healthcare Research and Quality (AHRQ) evaluated the use of SGAs in pediatric patients. This article summarizes the findings of the review, with a focus on bipolar disorder and schizophrenia.

scholarly journals Metabolic risk factor profile in patients on treatment with second generation antipsychotics

2016 ◽  
Vol 41 (3) ◽  
pp. 144-150
Author(s):  
Tahmina Zahan ◽  
Nargis Akhter ◽  
Mohammad Sayadul Islam Mullick ◽  
Zasmin Fauzia
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Body Mass Index ◽  
Bipolar Disorder ◽  
Body Weight ◽  
Adverse Effects ◽  
Body Mass ◽  
Second Generation ◽  
Density Lipoprotein ◽  
Second Generation Antipsychotics

The second generation antipsychotic agents, although exhibit superior safety profile, is associated with metabolic adverse effects including weight gain, diabetes mellitus and hyperlipidaemia. These adverse effects are not only the risk factors for cardiovascular disease and diabetes mellitus but may also impair patient’s adherence to treatment. However, different member of second generation antipsychotics differ in their extent of metabolic adverse effects. The aim of the study was to evaluate the association between olanzapine, risperidone or quetiapine treatment and body mass index, blood pressure, diabetes mellitus and hyperlipidaemia in patients with Schizophrenia and Bipolar Disorder. Forty-four cases of Schizophrenia and Bipolar Disorder diagnosed with DSM-IV criteria were selected according to inclusion and exclusion criteria. Body weight, body mass index and blood pressure were measured at baseline, at the end of 4th, 8th and 12th weeks of treatment. Blood samples were collected to measure blood glucose and serum lipid profile at baseline and at the end of 4th, 8th and 12th weeks in the study group receiving treatment (olanzapine 20-30 mg/day, risperidone 4-16 mg/day and quetiapine 300-800 mg/day) after overnight fasting. Therapeutic use of olanzapine and risperidone in Schizophrenia and Bipolar Disorder for a period of 4th, 8th and 12th weeks was associated with significant increase in body weight and body mass index. Quetiapine did not cause significant changes in body weight and body mass index after 4 and 8 weeks. However, after 12 weeks treatment, body mass index increased significantly. Olanzapine, risperidone and quetiapine increased the blood glucose level significantly after 8 and 12 weeks treatment. Olanzapine and risperidone elevated the serum cholesterol, triglyceride and low density lipoprotein levels significantly after 4, 8 and 12 weeks. But quetiapine showed no significant change in lipid profile. However, olanzapine and risperidone significantly increased triglyceride level after 8 and 12 weeks. Amongst three drugs, quetiapine treatment increased high density lipoprotein level. Our study revealed that quetiapine treatment is associated with less risk of dyslipidaemia.

Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents

2012 ◽  
Vol 32 (3) ◽  
pp. 309-316 ◽  
Author(s):  
David Cohen ◽  
Olivier Bonnot ◽  
Nicolas Bodeau ◽  
Angèle Consoli ◽  
Claudine Laurent
Keyword(s):  
Adverse Effects ◽  
Children And Adolescents ◽  
Second Generation ◽  
Second Generation Antipsychotics

Old drugs vs. new drugs: Treating bipolar disorder in children and adolescents

2011 ◽  
Vol 26 (S2) ◽  
pp. 277-277
Author(s):  
P.T. Dineen ◽  
A.L. Malizia
Keyword(s):  
Bipolar Disorder ◽  
Literature Review ◽  
Children And Adolescents ◽  
Pharmacological Treatment ◽  
Antipsychotic Drugs ◽  
Second Generation ◽  
New Drugs ◽  
Limited Evidence ◽  
Second Generation Antipsychotics ◽  
Old Drugs

This is a literature review of the evidence for pharmacological treatment for bipolar disorder in children and adolescents. The review covers drugs that have controlled studies and is divided into older, classical antimanic drugs and the newer mood-stabliser/antipsychotic drugs. The drugs that have had controlled studies are aripiprazole, lithium, olanzapine, oxcarbazepine, quetiapine, risperidone, topiramate, valproate/divalproex drugs and ziprasidone. Carbamazepine, lamotrigine and nefazodone (which is included for completion) were not found to have any evidence from controlled studies. Of the 9 drugs that have evidence, it was found that the newer second-generation antipsychotics had better evidence for efficacy for management of acute mania in children and adolescents: aripiprazole, risperidone, quetiapine and olanzapine. Classical antimanic agents such as lithium and valproate-based drugs had limited evidence.

Poster #S2 CARDIOMETABOLIC ADVERSE EFFECTS OF SECOND-GENERATION ANTIPSYCHOTICS IN DRUG NAÏVE CHILDREN AND ADOLESCENTS IN ACUTE CARE

2014 ◽  
Vol 153 ◽  
pp. S88
Author(s):  
Marco Armando ◽  
Luigi Mazzone ◽  
Valeria Lucarelli ◽  
Valentina Postorino ◽  
Maria Laura Pucciarini ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Children And Adolescents ◽  
Acute Care ◽  
Second Generation ◽  
Second Generation Antipsychotics ◽  
Drug Naïve
Sign in / Sign up

Export Citation Format

Share Document